The human immune response to the OKT3 monoclonal antibody is oligoclonal

Science ◽  
1986 ◽  
Vol 232 (4756) ◽  
pp. 1406-1408 ◽  
Author(s):  
L Chatenoud ◽  
M Jonker ◽  
F Villemain ◽  
G Goldstein ◽  
J. Bach
Keyword(s):  
Monoclonal Antibody ◽  
Immune Response ◽  
Human Immune Response ◽  
Human Immune

Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody

1984 ◽  
Vol 14 (8) ◽  
pp. 686-691 ◽  
Author(s):  
Marc-Francois Baudrihaye ◽  
Lucienne Chatenoud ◽  
Henry Kreis ◽  
Gideon Goldstein ◽  
Jean-Francois Bach
Keyword(s):  
Monoclonal Antibody ◽  
Immune Response ◽  
Human Immune Response ◽  
Human Immune

Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial

1992 ◽  
Vol 21 (1-3) ◽  
pp. 109-120 ◽  
Author(s):  
Surinder K. Sharma ◽  
Kenneth D. Bagshawe ◽  
Roger G. Melton ◽  
Roger F. Sherwood
Keyword(s):  
Clinical Trial ◽  
Monoclonal Antibody ◽  
Immune Response ◽  
Human Immune Response ◽  
Human Immune

scholarly journals Assessing the human immune response to SARS-CoV-2 variants

2021 ◽  
Vol 27 (4) ◽  
pp. 571-572 ◽  
Author(s):  
Roberto Burioni ◽  
Eric J. Topol
Keyword(s):  
Immune Response ◽  
Human Immune Response ◽  
Human Immune

scholarly journals Approaches to Modelling the Human Immune Response in Transition of Candidates from Research to Development

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Diane Williamson
Keyword(s):  
Immune Response ◽  
Human Immune Response ◽  
Human Immune ◽  
Animal Rule

This review considers the steps required to evaluate a candidate biodefense vaccine or therapy as it emerges from the research phase, in order to transition it to development. The options for preclinical modelling of efficacy are considered in the context of the FDA’s Animal Rule.

Sign in / Sign up

Export Citation Format

Share Document